Information has been received regarding a case in litigation concerning a minor male patient who was exposed to high levels of mercury from thimerosal through exposure to unspecified products. In addition the patient was exposed to mercury from continually inhaling and ingesting mercury emissions from fossil fuel driven power plants. The mercury included in thimerosal laden products and power plant emissions together caused the patient to suffer from serious and permanent neurological injuries. The patient was exposed to airborne mercury vapor and mercury through food chain. the exposure to airborne mercury in the environment through inhalation, the food chain, and other sources contributed to the cumulative mercury toxicity and was a substantial factor in causing his neurological damage. It was noted that the patient had a heightened vulnerability to suffer neurological injuries from industrial mercury as a direct result of thimerosal exposure. As a direct and proximate cause of the toxic mercury exposure to the patient, minor male was caused to suffer serious and permanent neurological damage which included past and future mental, intellectual, developmental and neurological incapacity and associated learning disabilities, disorders and impairments. Upon internal review, serious and permanent neurological damage which included past and future mental, intellectual, developmental and neurological incapacity and associated learning disabilities, disorders and impairments and cumulative mercury toxicity were considered to be other important medical events (OMIC). No further information is available. Additional information has been received from medical records regarding a case in litigation concerning a minor male patient who weighed 7 pounds 14 ounces at birth who on 23-JUL-1997 was vaccinated in the right thigh with the first dose of hepatitis B virus vaccine rHBsAg (yeast) and on 12-SEP-1997, the patient was vaccinated in the right thigh with the second dose of hepatitis B virus vaccine rHBsAg (yeast) (Lot #623500/081E). On 21-OCT-1997, the patient received Trihibit and Orimune. On 16-DEC-1997, the patient received the second dose of Trihibit and Orimune. The patient had lead poisoning at the age of one year. The lead level was 10 and there was no treatment involved. On 26-MAR-1998, the patient received a third dose of Trihibit and a third dose of Orimune and a first dose of ActHib. On 10-SEP-1998 the patient was vaccinated in the left thigh with secondary suspect therapy MMRII (Lot# 621620/0024H) and received PPD Tine test. It was reported the patient walked at 15 months. On 25-JAN-1999, the patient received an ActHib booster, and in the left thigh Trihibit booster and DPT booster. On 09-AUG-1999, the patient received in the right deltoid a third dose of hepatitis B virus vaccine rHBsAg (yeast) (Lot# 628748/140H). On 01-AUG-2000, the patient was vaccinated in the left arm with varicella virus vaccine live (Lot# 634496/0535K). On 08-FEB-2002, the patient was vaccinated with the second dose of secondary suspect therapy MMRII (Lot# 639571/1207L), Ipol and Trihibit. On an unreported date, the patient was diagnosed with developmental delay and autism features. It was reported the patient needed constant care, he had daily living difficulties with dressing, bathing. It was reported that the patient's condition was stable and could be controlled with treatment. On 05-OCT-2001, the four year old patient whose reported weight was 44 pounds and head circumference was 51 centimeters was seen by a physician to evaluate his developmental delay. The patient had longstanding history of Attention Deficit/Hyperactivity Disorder (ADHD). It was reported that due to the patient's uncooperativeness, he was unable to have a hearing test. Developmentally, the patient said his first word at age 4 years old. It was reported that the patient was alert. It was reported that the patient had four seemingly "normal" half sisters. At the time of the office visit, the patient was assessed with developmental delay and autistic features. The physician strongly recommended that the patient be enrolled in a special education program. On 12-JUN-2003, it was reported that the patient always had loose stools 4/day, rule/out milk intestine. The patient had laboratory evaluation for hemoglobin, hematocrit and lead. On 13-MAR-2003, the patient had a clinical evaluation, which the Childhood Autism Rating Scale revealed a total score of (31), which suggested that he had mild characteristics of autism in terms of overall development. It was recommended that the patient be within hand reach at all times or he would wander about without fear of the consequences of his behavior. The patient exhibited limited social and emotional skills and appeared cognitively deficient. It was recommended that the patient be involved in highly structured environment with counseling and a strict intervention behavioral plan. Diagnostic impressions of the patient were the following: Pervasive developmental disorder, Phonological disorder, Attention Deficit hyper activity disorder, combined type, mixed receptive-expressive language disorder, mild mental retardation, history of speech and language delay, and a history of severe global development delays, psychosocial stressors, environmental problems, peer relational problems, academic problems, attentional problems and severe developmental problems and global function.  Follow-up information on 12-SEP-2006, contained the following adverse experience: loose stools, (June 2003). Upon internal review, it was determined that Autism, Pervasive developmental disorder, and mild mental retardation were considered important medical events (OMIC). Additional information has been requested. All available medical records will be provided upon request.